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SUMMARY
Multiple myeloma (MM) evolves from a highly prevalent premalignant condition termed MGUS. The
factors underlying the malignant transformation of MGUS are unknown. We report a MGUS/MM phe-
notype in transgenic mice with Em-directed expression of the XBP-1 spliced isoform (XBP-1s), a fac-
tor governing unfolded protein/ER stress response and plasma-cell development. Em-XBP-1s eli-
cited elevated serum Ig and skin alterations. With age, Em-xbp-1s transgenics develop features
diagnostic of humanMM, including bone lytic lesions and subendothelial Ig deposition. Furthermore,
transcriptional profiles of Em-xbp-1s lymphoid and MM cells show aberrant expression of known hu-
man MM dysregulated genes. The similarities of this model with the human disease, coupled with
documented frequent XBP-1s overexpression in human MM, serve to implicate XBP-1s dysregula-
tion in MM pathogenesis.
Open access under CC BY license.INTRODUCTION
Multiple myeloma (MM) is a multifocal plasma-cell neo-
plasm characterized by serum monoclonal gammopathy
and focal skeletal lesions. MM is preceded by a premalig-
nant condition, monoclonal gammopathy of undeter-
mined significance (MGUS), present in 1% of adults over
the age of 25 and rising to 10% prevalence in individuals
in their tenth decade. The genetic and environmental fac-
tors underlying MGUS and its progression to MM are
largely unknown, although aberrant physiological re-
sponses to chronic immune stimulation are among thenumber of potential pathogenetic associations (Sirohi
and Powles, 2006). MM remains incurable despite con-
ventional high-dose chemotherapy and transplantation,
translating into a median survival of 6 years (Bergsagel
and Kuehl, 2005; Mitsiades et al., 2004).
Extensive genomic analysis has revealed a large num-
ber of genes and loci associated with the development
of MGUS and MM. Prominent cytogenetic events include
chromosomal translocations involving Ig loci juxtaposed
to the genesCyclin D1, FGFR3,MMSET, and c-MAF, driv-
ing their overexpression. Additional genetic events typi-
cally associated with disease progression include RasSIGNIFICANCE
The significance of this work is underscored by the presence of MGUS in 1%–10% of adults, with 1%–3% pro-
gressing to MM annually. The genesis and progression of the disease are poorly understood, and the generation
of a mouse model recapitulating many aspects of MGUS and MM provides an opportunity for the systematic
dissection of the biological processes underlying disease progression. In particular, this genetically engineered
MM-prone model enables validation of emerging MM-relevant (epi)genetic alterations and guides development
of effective therapies targeting such validated rate-limiting aberrations. This genetic study and analysis of clinical
samples suggest a pathogenetic role for sustained XBP-1s expression in the neoplastic transformation of plasma
cells, indicating that chronic cellular stress contributes to the development of this common neoplasm.Cancer Cell 11, 349–360, April 2007 ª2007 Elsevier Inc. 349
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Mouse Model of Multiple Myelomaand FGFR3 activating mutations; c-MYC deregulation;
p16INK4A, p18INK4C, TP53, and PTEN tumor suppressor
gene inactivation; and chromosome 13 deletion (Bergsa-
gel and Kuehl, 2005; Kuehl and Bergsagel, 2002). Recent
genomic studies have provided evidence of many addi-
tional genetic lesions driving human MM pathogenesis
(Carrasco et al., 2006). The availability of a MM mouse
model would facilitate the identification and validation of
these MM-relevant genes and provide a preclinical model
for assessing therapeutic agents directed against such
targets.
Many experimental efforts to generate mouse models of
B cell neoplasms, including MM, have typically involved
targeted oncogene expression in the B cell compartment
by transgenic and knockin approaches, alone or together
with various tumor suppressor gene mutations (Cheung
et al., 2004; Park et al., 2005). These modeling strategies
have generally yielded B cell malignancies displaying im-
mature phenotypes or plasmacytomas rather than classi-
cal MM. It is worth noting that mice do possess the inher-
ent capacity to develop a spontaneous condition similar to
human MGUS and MM, as evidenced by the capacity of
the C57BL/KaLwRij strain to develop a plasma-cell dys-
crasia, monoclonal gammopathy, and bone lytic lesions,
albeit with late onset (after 2 years), low incidence (0.5%),
and a propensity of these malignant plasma cells to home
to lymphoid tissues other than the bone marrow (Garrett
et al., 1997). Furthermore, the intravenous transplantation
of these myeloma cells into syngeneic hosts has gener-
ated a single cell-line model that generates characteristic
myeloma bone disease (Garrett et al., 1997). Along the
lines of disease representation, it is worth noting that hu-
man MM consists of a minimum of four molecular sub-
types (Carrasco et al., 2006) and that available human
MM cell lines only partially represent these disease cate-
gories (D.R.C., G.T., and R.A.D., unpublished data). To-
gether, these observations underscore the need for the
continued development of genetic and cell-line models
that capture the full range of genetic and biological diver-
sity of human MM.
Based upon the above efforts to construct MM mouse
models, we hypothesized that enforced B cell lineage-di-
rected transgene expression of factors driving plasma-cell
differentiation, alone or together with classical myeloma
genes, would enhance the development of a MM-like dis-
ease. XBP-1 is a basic-region leucine zipper (bZIP)
transcription factor of the CREB-ATF family and a major
regulator of the unfolded protein response (UPR) and
plasma-cell differentiation. XBP-1-deficient embryos die
in utero from severe liver hypoplasia and resultant fatal
anemia. Viable chimeras derived from XBP-1 null ES cells
injected into Rag2 blastocysts reveal that XBP-1-deficient
B cells proliferate and form germinal centers, yet there is
a profound impairment in Ig secretion and absence of
plasma cells (Reimold et al., 2001). XBP-1 is subject to
alternative RNA processing, generating two mRNA tran-
scripts encoding the same N-terminal DNA binding do-
main, but different C-terminal transactivation domains.
The shorter spliced transcript, designated XBP-1s, pos-350 Cancer Cell 11, 349–360, April 2007 ª2007 Elsevier Inc.sesses enhanced transactivation potential and stability
relative to the product of the unspliced transcript, desig-
nated XBP-1u (Iwakoshi et al., 2003b; Lee et al., 2002;
Shen et al., 2001). Thus, XBP-1u has no appreciable trans-
activation potential and may function as a dominant neg-
ative of XBP-1s (Lee et al., 2003).
Recent studies have uncovered several functions for
XBP-1 and have implicated XBP-1 overexpression in hu-
man carcinogenesis and tumor growth under hypoxic con-
ditions. Specifically, elevated XBP-1 mRNA levels have
been detected in hepatocellular carcinomas (Lee et al.,
2002) and in primary ERa-positive breast tumors (Fujimoto
et al., 2003; Iwakoshi et al., 2003a). With regard to MM,
abundant expression of XBP-1 has been detected in hu-
man MM cells (Munshi et al., 2004) and can be induced
by IL-6, a growth factor for malignant plasma cells (Wen
et al., 1999). However, these studies did not provide defin-
itive documentation of the particular XBP-1 isoform prefer-
entially produced in human MM or provide insights into the
pathophysiological relevance of these XBP-1 isoforms in
MGUS and MM (Davies et al., 2003; Munshi et al., 2004).
In this study, we have explored the biological impact of
sustained XBP-1s expression in the lymphoid system, an-
ticipating that this genetic event would be a necessary
component along with other MM-relevant oncogenes and
tumor suppressor gene manipulations to generate a MM-
prone mouse model. Unexpectedly, XBP-1s overexpres-
sion alone yielded a MGUS-MM disease bearing many
features that are classic hallmarks of the human disease
on the clinical, pathological, and molecular levels. These
genetic observations were bolstered by an analysis of clin-
ical samples documenting frequent XBP-1s overexpres-
sion in human MM samples relative to normal plasma cells,
together implicating XBP-1s dysregulation in the genesis
of this malignancy. This murine model of MGUS-MM
provides a framework for understanding the molecular
and biological mechanisms governing the genesis and
progression of these common and enigmatic plasma-
cell dyscrasias.
RESULTS
XBP-1 Expression in Human Normal Plasma Cells
and MM Cells
The unanticipated MM-prone condition in our mouse
model (see below) and previous studies documenting in-
creased XBP-1 expression in human MM (Davies et al.,
2003; Munshi et al., 2004) prompted detailed XBP-1 ex-
pression studies in clinical samples. Tissue microarray im-
munohistochemical (TMA-IHC) and western blot assays
were used to examine the relative levels and patterns of
XBP-1 and its isoforms in normal human plasma cells,
MGUS, and MM. As shown in Figure 1A, TMA-IHC analy-
sis of bone marrow tissues derived from healthy donors
and from MGUS and MM patients revealed low or unde-
tectable XBP-1 protein expression in the plasma cells
from ten healthy donors yet robust and widespread
XBP-1 expression in 10/20 (50%) of MGUS and 50/70
(70%) of MM samples. Consistent with the IHC data,
Cancer Cell
Mouse Model of Multiple MyelomaFigure 1. Predominance of the Spliced Form of XBP-1 over the Unspliced Form in MM Primary Tumors
(A) Immunohistochemical analysis for XBP-1 expression was performed on bone marrow tissue microarrays from healthy (PCs) donors (n = 10) and
MGUS (n = 20) and MM (n = 70) patients. Representative results are shown. CD138 is stained in red, and XBP-1 is stained in brown. Scale bars, 50 mm
(10 mm in insets).
(B) Plasma cells were isolated from the bone marrow of healthy donors (lanes 1 and 2) and MM primary tumors (lanes 3–24) using CD138 magnetic
beads, and total protein extract (40 mg per lane) was subjected to western blot analysis using anti-XBP-1 antibodies.
(C)Total protein extract (20 mg) from CD138 purified normal plasma cells (PC), MM primary tumors (MM), the MM1S MM cell line treated with 10 mg/ml
of Tunicamycin (TM) and untreated (NT) for 4 hr, and 293T cells lentivirally infected with XBP-1s (Pos. Control) were electrophoresed and subjected to
western blot analysis using XBP-1 antibodies. Protein loading was assessed by Ponceau staining and Ig light-chain immunostaining.
(D) Total protein extracts (40 mg per lane) from CD138-purified normal plasma cells (PC) and MM cell lines were subjected to western blot analysis
using XBP-1 antibodies.
(E) Immunofluorescence analysis of XBP-1 expression on MM1S cell line. Scale bars, 50 mm.western blot analysis of protein extracts from 22 samples
of CD138+ MM cells demonstrated a prominent shift to-
ward increased XBP-1s expression in the majority of
MM primary tumor samples relative to normal plasma cells
(Figures 1B and 1C), a pattern also evident in MM cell lines
(Figures 1C–1E). These correlative translational observa-
tions and the known capacity of XBP-1 to drive expression
of MM-promoting factors such as IL-6 (Iwakoshi et al.,
2003b and see below) prompts speculation that chroni-
cally increased levels of XBP-1s may contribute to the
development of human MGUS and MM.
Generation of Em-xbp-1s Transgenic Mice
Expressing XBP-1s in B Cells and Plasma Cells
On the basis of XBP-1s prominence in human MM and its
potent transactivation potential (Iwakoshi et al., 2003a),
we generated and characterized transgenic mice engi-
neered to express the xbp-1s open reading frame under
the control of the immunoglobulin VH promoter and Em
enhancer elements (Em) (Figure 2A). Nine founders were
obtained for the Em-xbp-1s transgene, and Southern
blot comparison of the endogenous (WT) and transgenicxbp-1shybridization signals (TG) indicated transgene copy
numbers ranging from approximately 1 to 15. The South-
ern blot shown in Figure 2B documents three of the nine
founders in one representative litter derived from C57BL/
6-microinjected oocytes (Figure 2B; other founder blots
not shown). Two independent founder lines, S.7 and S.9,
and their transgenic progeny, were propagated and used
in this study.
In accord with the known capacity of Em regulatory ele-
ments to drive transgene expression throughout B cell de-
velopment, as well as in some T cells (Kemp et al., 1980),
robust Em-xbp-1s transgene expression was detected in
the spleen, lymph nodes, thymus, and bone marrow of all
nine founders, including S.7 and S.9 progeny, as deter-
mined by eGFP expression (Figure 2C, only S.7 shown).
Analysis of purified splenic B cells using the pan-B cell
marker B220 from 6-week-old Em-xbp-1s transgenic and
control mice showed increased levels of the spliced
xbp-1s transcript in the transgenic mice correlating with
transgene DNA copy number (Figure 2D and data not
shown). Correspondingly, western blot analysis of B220+
splenic B cells confirmed elevated XBP-1s protein levelsCancer Cell 11, 349–360, April 2007 ª2007 Elsevier Inc. 351
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Mouse Model of Multiple MyelomaFigure 2. Generation and Characterization of Em-xbp-1s Transgenic Mice
(A) Transgenic construct. The xbp-1s cDNA encoding the spliced form of mouse XBP-1 was cloned downstream of the immunoglobulin VH promoter
and Em enhancer (pEm) elements. In addition to expressing XBP-1s, the transgene also encodes a farnesylated eGFP coding sequence behind an
IRES element.
(B) Southern blot genotyping of Em-xbp-1s transgenic mice was done on EcoRI-digested genomic tail DNA and hybridized with a radiolabeled probe
encoding 50 sequences from the mouse xbp-1s cDNA. Note genomic xbp-1 sequences (WT) as well as transgenic sequences (TG). Only three of nine
founders are shown.
(C) High levels of transgene expression in spleen, lymph nodes, and thymus as evaluated by eGFP western blot analysis on total organ protein ex-
tracts isolated from 6-week-old control and transgenic mice.
(D) RT-PCR analysis using mRNA from purified mouse B cells from Em-xbp-1s transgenic (S.1, S.7, S.9) and control (WT) mice. The 171 bp and 145 bp
DNA fragments correspond to unspliced and spliced xbp-1 mRNAs, respectively.
(E) Western blot analysis of Em-xbp-1s transgenic (S.1, S.7, and S.9) and control (WT) splenic B220+ B cells.
(F) Immunofluorescence staining of control (WT) and Em-xbp-1s transgenic splenic B cells. Scale bars, 10 mm. The genomic DNA, mRNA, and protein
extracts were isolated from 6-week-old transgenic and control littermates.(Figure 2E), and anti-XBP-1 immunofluorescence showed
stronger nuclear staining in Em-xbp-1s transgenic B cells
compared with nontransgenic B cell controls (Figure 2F).
Together, these assays documented increased XBP-1s
protein levels in the murine B lineage, enabling an in vivo
analysis of the functional impact of enforced XBP-1s ex-
pression in B cell and plasma-cell compartments. To that
end, all nine founders and the S.7 and S.9 progeny were
assessed clinically using histological and flow cytometric
analysis of lymphoid cells. While detailed phenotypic anal-
ysis described below focused on the two independent
transgenic lines, S.7 and S.9, and their progeny, the same
phenotype was observed in all nine founders.
Em-xbp-1s Transgenic Mice Show Cutaneous
and Renal Pathologies Resembling Patients
with Chronic Plasma-Cell Disorders
Through 20 weeks of age, Em-xbp-1s transgenic mice ex-
hibited normal gross appearance, behavior, and weight
curves. Histological surveys of the major organs, as well
as flow cytometric profiles of spleens using the lymphoid
cells markers CD3 and B220, did not demonstrate any ab-
normalities (data not shown). By approximately 40 weeks
of age, Em-xbp-1s transgenic animals began to manifest
phenotypic changes in the skin and kidneys. Em-xbp-1s
transgenic mice exhibited an overall shortened life span
resulting from severe cutaneous disease and/or myeloma
(Figure 3A; see below). Sixty percent of Em-xbp-1s trans-352 Cancer Cell 11, 349–360, April 2007 ª2007 Elsevier Inc.genic mice developed hair loss and skin thickening around
axillary and neck regions, whereas control littermates were
unaffected (Figure 3B and data not shown). This cutane-
ous presentation was observed in all independently de-
rived Em-xbp-1s transgenic lines. Histological examination
of the Em-xbp-1s skin revealed epidermal thickening and
some degree of hyperkeratosis with follicular plugging
as well as dermal fibrosis with mild lymphoplasmacytic in-
filtrates and vascular hyperplasia. It is notable that these
pathological changes are similar to those encountered in
patients with specific autoimmune conditions and a rare
plasma-cell disorder, termed POEMS (for polyneurop-
athy, organomegaly, endocrinopathy, serum monoclonal
protein, and skin lesions) (Dispenzieri, 2005) (Figure 3B).
By 40 weeks, Em-xbp-1s transgenic mice also showed
renal pathology, including tubular cast deposition
(Figure 3C, white arrows) and glomerular changes charac-
terized by mesangial widening and deposition of PAS-
positive material (Figure 3C, yellow arrows). Transmission
electron microscopy showed mesangial and subendothe-
lial deposition of electron-dense material (Figure 3C, black
arrows). These renal lesions are similar to the pathologic
manifestations present in human MM and other plasma-
cell disorders with systemic chronic Ig overproduction and
accumulation of light chains (light-chain cast nephropa-
thy), paraproteins, and other Ig fragments (Herrera et al.,
2004). To assess whether these lesions were Ig deposits,
immunofluorescence with antibodies specific for light- and
Cancer Cell
Mouse Model of Multiple MyelomaFigure 3. Survival, Skin, and Renal Alter-
ations in Em-xbp-1s Transgenic Mice
(A) Disease-free survival (lack of skin alter-
ations) in Em-xbp-1s transgenic mice. Statisti-
cally significant differences (p < 0.0001) were
detected between Em-xbp-1s transgenic and
control littermates.
(B) Skin alterations in Em-xbp-1s transgenic
mice. Note loss of hair and skin thickening in
axillary region. Histological H&E sections
showing dermal changes in Em-xbp-1s trans-
genic mice. Note epidermal thickening, dermal
fibrosis, and vascular proliferation (insets).
Scale bars, 1.0 cm (left panel), 50 mm (middle
and left panels), and 20 mm (insets).
(C) Renal tissue sections from 40-week-old
control (WT) and Em-xbp-1s transgenic mice
were stained with H&E, PAS, or subjected
to electron microscopic analysis (EM). White
arrows, tubular protein deposition; yellow ar-
rows, mesangial protein deposition; black
arrows, subendothelial deposits. Scale bars,
50 mm (H&E), 20 mm (PAS), 0.1 mm (EM).
(D) Glomerular immunoglobulin deposition. Se-
rial frozen renal sections from control (WT) and
Em-xbp-1s tissue sections were analyzed by
immunofluorescence using specific antibodies
for mouse immunoglobulin kappa and lambda
light chains, as well as IgA, IgG, and IgM heavy
chains. Scale bars, 20 mm.Cancer Cell 11, 349–360, April 2007 ª2007 Elsevier Inc. 353heavy-chain Ig was performed. Nonspecific trapping of
light- and heavy-chain Ig was present and consisted of ei-
ther polyclonal heavy and light chains or clonal IgM or IgG
heavy chain and kappa light chains (Figure 3D and data
not shown). To determine whether amyloid depositions
were present, a feature occasionally seen in MM patients,
Congo red stains performed across several tissues and in-
dependent cell lines were negative (see Figure S1A in the
Supplemental Data available with this article online) sug-
gesting that amyloid deposition, which is observed rarely
(5%–15%) in human MM patients (Kyle and Gertz, 1990),
is not a feature of the Em-xbp-1s disease model.
Altered Proliferative Potential of Splenic B Cells
and Hypergammaglobulinemia in Em-xbp-1s
Transgenic Mice
Serial gross, histological, and flow cytometric examination
of the spleen and bone marrow of Em-xbp-1s transgenic
mice showed alterations after 20–40 weeks of age. Thespleens appeared slightly enlarged and showed increased
plasma cells around periarterial sheaths (Figure S1B, ar-
rows). Flow cytometric analysis showed unaltered total
numbers of T cell (CD3) and B cell (B220) populations in
Em-xbp-1s transgenic spleens (Figure S2A). The total
number of mononuclear cells between wild-type (8.05 3
107 ± 0.5) and Em-xbp-1s transgenic (7.95 3 107 ± 1.5)
spleens did not differ. Em-xbp-1s transgenic mice at
40 weeks of age showed a slightly enlarged population of
CD23+ cells (49.1% ± 3.9% versus 40.2% ± 0.1%) and
a reciprocal decrease in CD23 cells (43.3% ± 1.5% ver-
sus 53.4% ± 1.9%). We observed a trend toward in-
creased number of precursor and mature follicular cells
T2/M cells (CD23+/CD21+/IgM+ cells) (34.1% ± 1.2% ver-
sus 26.4% ± 1.4%) as well as marginal zone (MZ) B cells
(CD23IgMhiCD21+ cells) (3% ± 0.1% versus 1% ±
0.0%) in the spleens of Em-xbp-1s transgenic mice
(Figure S2B). In addition, the fraction of B220+ cells in the
bone marrow was significantly increased in Em-xbp-1s
Cancer Cell
Mouse Model of Multiple MyelomaFigure 4. Hypergammaglobulinemia,
BoneMarrowPlasmacytic Infiltrates, and
Bone Lytic Lesions in Em-xbp-1s Trans-
genic Mice
(A) Marked elevation of serum immunoglobulin
levels in Em-xbp-1s transgenic mice. Serum
plasma from control (WT) and Em-xbp-1s trans-
genic mice were measured by ELISA, protein
serum electrophoresis, and densitometry. Note
the presence of M spike (arrow) in Em-xbp-1s
transgenic mice. Representative bone marrow
biopsies from control and Em-xbp-1s trans-
genic mice were analyzed by light microscopy
(H&E) to reveal increased plasma-cell infiltrates
in the marrow of Em-xbp-1s transgenic mice.
(B) Bone lytic lesions in Em-xbp-1s transgenic
mice. Femurs from control (WT) and Em-xbp-
1s transgenic mice were dissected to detect
the presence of bone lytic lesions by X-ray
(white arrows) and immunohistochemical anal-
ysis (black arrow). B, cortical bone. Scale bars
20 mm (upper panel), 0.5 cm (lower panels, fe-
mur), 0.25 cm (insets), 50 mm (CD138).transgenic mice with an increase in the mature IgM+B220+
B cell population (17.2% ± 1.2% versus 10.8% ± 0.2%)
and a relative decrease of pro-B cells (B220+CD43+) in re-
lation to pre-B cells (B220lowCD43) in Em-xbp-1s trans-
genic bone marrows (Figure S2B).
Overall, these studies reinforce the view that enforced
XBP-1s expression has an impact beyond the well-estab-
lished role of this transcription factor in the terminal differ-
entiation of B cells into plasma cells (Shaffer et al., 2004).
Consistent with the above observation of expanded B
cell compartment, plasma immunoglobulin levels of both
IgM and IgG types by ELISA were significantly increased
in Em-xbp-1s transgenic mice (Figure 4A). Serum protein354 Cancer Cell 11, 349–360, April 2007 ª2007 Elsevier Inc.electrophoresis (SPEP) revealed presence of an M spike
(Figure 4A, arrow) in the majority of Em-xbp-1s transgenic
mice, but not in control littermates as early as 20 weeks of
age—a feature that increased in frequency and magnitude
with advancing age (data not shown). Notably, these se-
rum changes were associated in some cases with bone
lytic lesions and increased numbers of plasma cells in
the bone marrow that varied from 5%–30% of the total
bone marrow cellularity compared with <5% for nontrans-
genic controls (Figures 4B and 5A; Table S1).
On the molecular level, transcriptome comparison of
Em-xbp-1s and nontransgenic B cells (n = 5 mice each)
by significance analysis of microarrays (SAM) (TusherFigure 5. Evidence of Clonality and Hy-
permutation of Expressed Ig Genes in
Em-xbp-1s Transgenic Mice
(A) IHC analysis of plasma-cell clonality from
bone marrow biopsies. Scale bars, 50 mm
(10 mm in insets).
(B) Southern blot analysis for clonotypic
immunoglobulin heavy-chain rearrangement in
Em-xbp-1s myeloma tumors. High-molecular-
weight DNA was isolated from snap-frozen
control or myeloma marrows, digested with
EcoRI restriction enzyme, and hybridized
with a 1.9 BamHI-EcoRI genomic probe frag-
ment downstream and adjacent to the mouse
heavy-chain locus JH segment. GL denotes
the germline band.
(C) DNA sequence chromatograms of PCR
products detect mutations in the 30 JH4 region
of rearranged variable (V) genes in Em-xbp-1s
tumors.
Cancer Cell
Mouse Model of Multiple MyelomaFigure 6. Altered Gene Expression of
Em-xbp-1s B Cells and Tumor Plasma
Cells and Increased Apoptosis of Tumor
Plasma Cells
(A) Ingenuity analysis showing altered expres-
sion of Cyclin D1 and c-MAF in myeloma tu-
mors. In red are significantly overexpressed
genes and in green are downregulated genes.
Color intensity is proportional to the SAM score
(Tusher et al., 2001).
(B) Western blot analysis showing activation
of caspase-3, as well as decreased c-JUN,
c-FOS, MCL1, and BCL2 in transgenic B cells
and MM tumors as compared to wild-type
samples.
(C) IHC showing increased apoptosis
(Apoptag) and proliferation index (Ki-67) in
Em-xbp-1s myeloma primary mouse tumors
(PT) as compared with human myeloma tumors
(hMM). Scale bars, 50 mm (20 mm in insets).et al., 2001) revealed 1119 genes that were differentially
expressed (false discovery rate [FDR] = 1%), 808 upregu-
lated and 311 downregulated in Em-xbp-1s B cells versus
nontransgenic B cells. Among the genes selectively al-
tered in Em-xbp-1s B cells are those with known relevance
to human MM pathogenesis, such as Cyclin D1, Cyclin D2,
MAF, and MAFB (Figure 6A and data not shown) (Kuehl
and Bergsagel, 2002; Shaffer et al., 2004). Given the role
of these genes in cell-cycle regulation, proliferative poten-
tial of wild-type and transgenic B cells were examined
ex vivo. Consistent with the molecular changes, Em-xbp-
1s transgenic B cells exhibited increased incorporation
of thymidine relative to nontransgenic controls (Fig-
ure S2C, p = 0.002). Enhanced proliferative potential of
the transgenic B cells was also observed in response to
stimulation with B cell activators CD40, anti-IgM, or
CD40 together with anti-IgM (data not shown).
Knowledge-based pathway analysis (Calvano et al.,
2005) of the 1119 SAM-significant genes also revealed al-
terations in several pathways (p < 0.0001). A notable MM-
relevant pathway that was prominently altered is IL-6,
where the two components of the IL-6 receptor, IL-6R
and gp130, show significant upregulation, along with three
members of the CEBP family, CEBPA, CEBPB, andCEBPD, in addition to several downstream targets of
these transcriptional factors, such as ALOX5, LITAF,
MMP8, and IFITM3 (Figure S3A). Prompted by this obser-
vation, we examined the level of serum IL-6, to determine
whether a more general dysregulation of this pathway was
present in these mice. Consistent with the activation
of this pathway, serum IL-6 levels were increased in
Em-xbp-1s transgenic mice relative to control littermates
(Figure S2C, p < 0.005), while the plasma levels of other
cytokines, including IL-2, IL-4, IL-5, and IL-10, were un-
changed (data not shown).
Taken together, the phenotypic and molecular analyses
of transgenic and nontransgenic B cells uncovered can-
cer-relevant biological consequences of XBP-1s over-
expression, including B cell hyperproliferation and IL-6
activation, both of which are plausible mechanisms capa-
ble of driving plasma-cell transformation.
Spontaneous MGUS and MM in Aging Em-xbp-1s
Transgenic Mice
The above constellation of findings prompted detailed
analysis of aging Em-xbp-1s and nontransgenic controls
for evidence of MGUS and/or MM. As early as 40 weeks
of age, a classical MGUS profile emerged only in theCancer Cell 11, 349–360, April 2007 ª2007 Elsevier Inc. 355
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Mouse Model of Multiple MyelomaEm-xbp-1s transgenic mice. Between 11 and 20 months of
age, approximately 26% (9/35) of Em-xbp-1s transgenic
mice showed a clonal M spike in the serum and expanded
populations of clonal plasma cells in the bone marrow
(<10% of the total bone marrow mononuclear cells), with-
out bone lytic lesions and consistent with a pattern of
MGUS (Table S1; data not shown). Between 14 and 24
months of age, 26% (8/35) of Em-xbp-1s transgenic mice
progressed to frank MM as defined by a clonal M spike in
the serum, bone marrow consisting of >10% of clonal
plasma cells, and associated bone lytic lesions on radio-
graphic examination (Figures 4A, 4B, and 5A; Table S1;
and data not shown). Clonality of the MM cells was evi-
denced by IHC of immunoglobulin heavy and light-chain
subtype expression, as performed in the clinical labora-
tory (Figure 5A), and by Southern blot analysis of IgH
gene rearrangement analysis in bone marrow plasma cells
(Figure 5B). In accord with the concept of a postgerminal
center cell derivation of human MM cells (Kuehl and
Bergsagel, 2002), some of the Em-xbp-1s MMs showed
evidence of somatic hypermutation between the body of
the 30 JH4 region of rearranged variable (V) genes
(Figure 5C). Neither MGUS nor MM was detected in con-
trol littermates at any age, indicating that XBP-1s overex-
pression promotes the development of a condition similar
to MGUS and MM. In summary, spontaneous progression
from MGUS to MM in the Eu-xbp-1s transgenic mice clin-
ically mirrors disease progression in the human.
To further compare this mouse model with the human
disease, we performed transcriptome profiling to define
the Em-xbp-1s myeloma signature. Transcriptome analy-
ses in the mouse identified 708 genes overexpressed
and 1784 genes downregulated (FDR = 1%) in Em-xbp-1s
MM cells relative to B cells from young neoplasm-free
Em-xbp-1s mice. Supporting a pathogenetic role for
XBP-1s overexpression in the myeloma genesis in this
model, several known MM genes that were dysregulated
in premalignant Em-xbp-1s B cells exhibited similar pat-
terns of alterations in XBP-1s MM cells, including Cyclin
D1, MAF, CEBPA, CEBPB, CEBPD, IL6ST (upregulated),
and FOS (downregulated). Conversely, some notable MM
signature genes were found to be selectively dysregulated
in Em-xbp-1s MM, but not in Em-xbp-1s B cells, in line with
the need for additional spontaneously occurring cooperat-
ing events as reflected in the long latency of the MM phe-
notype. Among such genes selectively upregulated in the
tumors were APRIL and BAFF, both of which have been
found to be overexpressed in various B cell malignancies,
including MM (He et al., 2004; Novak et al., 2004). How-
ever, unlike the human counterpart, the Em-xbp-1s MM
transcriptome revealed evidence of prominent activation
of proapoptotic tumor suppression mechanisms charac-
terized by downregulation of the antiapoptotic genes,
MCL1 and BCL2, which are typically upregulated or ampli-
fied in aggressive human MM cases (Carrasco et al., 2006;
Le Gouill et al., 2004; Mitsiades et al., 2004). Interestingly,
MCL1 and BCL2 were not downregulated in hyperprolifer-
ative premalignant transgenic B cells (Figure S3B and data
not shown). Consistent with the Em-xbp-1s gene expres-356 Cancer Cell 11, 349–360, April 2007 ª2007 Elsevier Inc.sion pattern and in contrast to the human disease, we
documented a marked increase in apoptosis and prolifer-
ation in murine MM samples relative to those in human
MM samples (Figures 6B and 6C). Such observations
gain added significance in light of the observation that
MCL1 maps to a region of gene amplification in aggressive
human MM primary tumors and prompt speculation that
MCL1 and BCL2 play critical roles in the progression of
human myeloma (Carrasco et al., 2006; Le Gouill et al.,
2004; Mitsiades et al., 2004)—a theory that can now be
tested in this genetic model system.
DISCUSSION
In this study, we provide genetic evidence and correlative
human data supporting a role for the differentiation and
unfolded protein/ER stress response factor X box binding
protein-1 spliced isoform (XBP-1s) in the development of
MGUS and MM. Our molecular and phenotypic analyses
of the XBP-1s-driven myeloma model implicate the
chronic ER stress response in MM pathogenesis.
A Genetically Engineered Mouse Model
of Human MM
In this Em-xbp-1s transgenic model, enforced XBP-1s
expression in the B cell compartment enhances B cell
proliferative potential and activates known MM-relevant
pathways, leading to the development of MGUS and
MM disease possessing many of the molecular, cellular,
and clinical features of the human condition. As in other
genetically engineered mouse (GEM) models of human
diseases, some differences do exist between the mouse
and human conditions, particularly in the levels of genome
instability. In addition, human MM is predominantly of IgG
isotype, but Em-xbp-1s MGUS and MM cases are either
the IgG isotype (50%) or the IgM isotype (50%). Another
difference is the prevalence of dermatitis and splenic plas-
macytosis in the mouse that, in humans, are more com-
monly encountered in patients with atypical plasma-cell
malignancies such as the POEMS syndrome and Castle-
man’s disease (Dispenzieri, 2005; Shahidi et al., 1995).
At the same time, there are remarkable similarities be-
tween the disease phenotypes in mice and humans.
These include progression from MGUS to MM accompa-
nied by bone marrow involvement with clonal plasma
cells, serum M spike, bone lytic lesions, and Ig deposition
in the kidney, all classical defining features of human MM.
Molecularly, Em-xbp-1s MM exhibited dysregulation of
several signature MM genes and pathways. For example,
expression alteration of genes such as Cyclin D1, gp130,
and MAF parallel the dysregulation of these genes identi-
fied in human MM cells, which are variously driven by re-
current chromosomal translocations, gene amplification,
and/or transcriptional mechanisms and represent essen-
tial elements in the genesis and progression of human
MM (Kuehl and Bergsagel, 2002). The proliferation effect
induced by IL-6 is mediated by the PI3K and MAPK path-
ways and through the activation of CEBPB. Given the
known role of the CEBP family of transcription factors in
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overexpression of CEBPB, as well as CEBPA and CEBPD,
may contribute to the strong proliferative drive of Em-XBP-
1s B transgenic cells that, through the acquisition of addi-
tional genetic/epigenetic lesions, could promote the de-
velopment of MGUS and MM. Additionally, CEBPB exerts
an inhibitory activity toward the AP1 complex, at both the
expression and transcriptional levels (Gagliardi et al.,
2003), demonstrated also in a human MM cell line (Take-
shita et al., 2004), that may be responsible for the low
JUN and FOS levels in the Em-xbp-1s B cells. Also, in ac-
cord with human MM, Em-xbp-1sMM cells exhibit overex-
pression of APRIL (a proliferation-inducing ligand). APRIL
is a member of the tumor necrosis family of ligands, which
also includes B lymphocyte stimulator/B cell activating
factor (BlyS/BAFF, which is also upregulated in Em-xbp-
1s MM cells), and these factors have been shown to serve
essential prosurvival roles in normal and malignant B lym-
phocytes. Increased expression of APRIL or BlyS have
been reported in various B cell malignancies, including
MM (He et al., 2004; Novak et al., 2004).
Taken together, these cross-species multilevel compar-
isons, spanning from molecular to organismal levels, pro-
vide a measure of validation that the Em-XBP-1s mouse
represents a relevant model of human MM, suggesting
its utility in the study of pathways known or presumed to
be altered in the human disease. In this regard, molecular
characterization of mouse and human MM has implicated
two antiapoptotic genes, MCL1 and BCL2, in MM pro-
gression. MCL1 and BCL2 are commonly amplified and
overexpressed in human MM (Carrasco et al., 2006; Le
Gouill et al., 2004; Spets et al., 2002); however, they were
downregulated in the Em-xbp-1s tumors (Figure 6B), but
not in premalignant B cells. This pattern of expression is
consistent with the observed increase in apoptosis in the
Em-xbp-1s mouse MM when compared to human MM
samples (Figure 6D), suggesting that active proapoptotic
mechanisms may be acting to constrain the MM pheno-
type in this model. Moreover, analysis of published data
comparing the expression level of plasma cells from
healthy donors, MGUS, and MM patients (Zhan et al.,
2002) indeed shows that only a subset of MM samples
have significantly higher MCL1 levels than healthy donors,
whereas MGUS patients and normal donors present com-
parable MCL1 expression (Figure S3B). These observa-
tions prompt speculation that MCL1 plays an especially
critical role in the progression of human MM and motivate
additional genetic modeling studies in Em-xbp-1s system
to formally test the role of MCL1 in MM progression.
Given the relatively long latency and low penetrance in
the appearance of MGUS and MM in this model, it stands
to reason that additional genetic lesions and pathway dys-
regulations are needed to develop MGUS and MM in the
Em-xbp-1s system. Indeed, several hallmark genes and
pathways linked to MM pathogenesis are altered at the
premalignant B cell level, for example Cyclin D1, Cyclin D2,
MAF, and MAFB, providing a proliferation impetus to pre-
cursor B cells and plasma cells. However, other genes are
consistently dysregulated specifically in the transition toMM, but not in Em-xbp-1s B cells or in the nontransgenic
B cells such as BAFF, APRIL, and several genes associ-
ated in MM human studies with a high degree of prolifera-
tion and poor prognosis (TOP2A, BIRC5, CCNB2, NEK2,
AURKA, BUB1, CDC2, and CDCA1; data not shown), sug-
gesting that other genetic and/or epigenetic additional le-
sions are needed to drive the progression into MGUS and
furthermore into MM. Therefore, Em-xbp-1s transgenic
mice constitute a valuable tool for in vivo testing of genetic
lesions capable of inducing MGUS and full-blown MM, on
the backdrop of a paraphysiological increase in plasma-
cell number.
Role of XBP-1s and ER Stress Response
in MM Pathogenesis
In humans, the XBP-1 gene has not been implicated in MM
pathogenesis because it does not reside in a region tar-
geted from chromosomal amplification and/or transloca-
tion in human MM tumors (Bergsagel and Kuehl, 2005;
Carrasco et al., 2006). However, there is evidence that
genes affecting XBP-1 processing are subject to genetic
changes, potentially leading to epigenetic dysregulation
of the XBP-1 network in MM. For example, the activating
transcription factor 6a (ATF6a), S1P, and S2P proteases,
as well as ER transmembrane protein kinase and endori-
bonuclease inositol-requiring enzyme-1a (IREa), are all
members of the proximal transducers of the mammalian
UPR (Ma and Hendershot, 2001). Furthermore, it is known
that XBP-1 activation/overexpression is a downstream
target (Gass et al., 2004) of the ER stress response path-
way, which is perturbed in the setting of viral infections
and inflammatory responses (Li et al., 2005). This gains
significance in light of the long suspected link between
autoimmunity and/or inflammation with MM (Sirohi and
Powles, 2006) as well as our genetic observations that
sustained XBP-1s overexpression alone is capable of driv-
ing MM development, raising the intriguing possibility that
this physiological stress response could have unwanted
‘‘side effects’’ that are of fundamental relevance to human
MM pathogenesis. In particular, we speculate that the
long-term survival of plasma cells and MGUS cells may
require enhanced activation of XBP-1s to handle the
high levels of antibody production and/or environmental
stresses. In this scenario, enhanced activation of XBP-
1s may lead to chronic IL-6 production and activation of
other MM-relevant circuits, ultimately driving progression
along the MGUS-MM continuum.
In summary, we propose Em-xbp-1s transgenic mouse
as a relevant model of human MGUS and MM. Addition-
ally, this genetic study, coupled with analysis of human
samples, highlights the potential importance of XBP-1s
in the pathogenesis of human MGUS and MM.
EXPERIMENTAL PROCEDURES
Transgenic Mice
The mouse xbp-1s cDNA (Calfon et al., 2002) was cloned into the
pBluescript II vector, which also contains a 1 kb fragment of the mouse
variable chain enhancer and promoter (pEm) and a 1.6 Kb fragment ofCancer Cell 11, 349–360, April 2007 ª2007 Elsevier Inc. 357
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signal sequence. The transgene also encoded farnesylated eGFP
coding sequences behind an IRES element. The transgenic encoding
sequences were released from the vector by BssHII digestion and
purified by zonal sucrose gradient centrifugation and microinjected
into C57BL/6 oocytes. Transgene-positive mice were mated with
C57BL/6 mice to generate transgenic and control littermates on the
same inbred C57BL/6 background for all subsequent analyses.
Screening of the transgenic founders and copy-number analysis
were done using Southern blot analysis with the entire xbp-1s cDNA
as a radiolabeled probe. Subsequent screening of transgenic mice
was done by PCR analysis using a set of GFP-specific primers (50-
ACGTAAACGG CCACAAGTTC-30 and 50-AAGTCGTGCT TCATGTG-
30 ). All animal experiments were approved by and conform to the stan-
dards of the Institutional Animal Care and Use Committee at the DFCI.
Mouse B220+ and Human Plasma-Cell CD138+ Isolation,
RNA Preparation, Expression Profiling, and Reverse
Transcription PCR
B220+ splenic B cells were isolated using magnetic microbeads from
Miltenyi Biotec. Plasma cells were isolated from human bone marrow
mononuclear cells from healthy donors (Cambrex BioScience) using
immunomagnetic bead selection with mouse anti-human CD138
monoclonal antibodies as described (Zhan et al., 2002), except that
we used LS MACS separation columns (Miltenyi Biotec) and before in-
cubating the bone marrow mononuclear cells to CD138-coated mag-
netic beads, we removed contaminating histiocytes and macrophages
by preloading and washing out the cells in the magnetic columns and
field. Total RNA was isolated from control and transgenic B220+
splenic mononuclear cells or myeloma tumors using TRIzol Reagent.
Affymetrix 430 2.0 arrays were hybridized at the DFCI Microarray
Core Facility. CEL files were obtained using Affymetrix Microarray
Suite 5.0 software. The DNA Chip Analyzer (dChip) was used to nor-
malize all CEL files to a baseline array with overall median intensity,
and the model-based expression (perfect match minus mismatch) was
used to compute the expression values. The same data were also an-
alyzed using the Ingenuity Pathways Analysis (Ingenuity Systems) soft-
ware. For SAM analysis, probes were included in the analysis if they
fulfilled the following criteria (Tonon et al., 2005): (1) SD > 0.3; (2)
>20% of samples with expression value > 100; (3) >20% of samples
with presence call.
The primers for xbp-1s cDNA were 50-ACACGCTTGG GAATGGA
CAC-30 and 50-CCATGGGAAG ATGTTCTGGG-30, which flanked the
spliced region in xbp-1s. PCR products were analyzed on a 3% aga-
rose gel. The Institutional Review Board of Brigham and Women’s
Hospital approved the human research studies, and all subjects pro-
vided written informed consent approving use of their samples for
research purposes.
X-Ray, Histopathology, and Immunohistochemistry
Bone X-ray was performed using Faxitron X-ray Specimen Radio-
graphic System and Kodak X-OMAT-TL films. Tissues were fixed, pro-
cessed, sectioned, and stained with hematoxylin-eosin (H&E) or PAS
for light microscopy examination by routine methods. Spine and fe-
murs were additionally treated for 1 hr in decalcifying solution (Fisher
Scientific). Immunohistochemistry was performed according to stan-
dard procedures. The anti-mouse XBP-1 rabbit polyclonal antibody
(M-186) was obtained from Santa Cruz Biotechnology. The rat anti-
mouse CD45R/B220 (RA3-6B2), rat anti-mouse CD138 (281-2), and
mouse anti-human/mouse Ki-67 (B56) monoclonal antibodies were
obtained from BD Biosciences. The primary antibodies were visualized
with the corresponding biotinylated antibody coupled to streptavidin-
peroxidase complex (Vector Labs). The goat anti-mouse polyclonal
antibodies for immunoglobulin heavy chains IgA, IgM, IgG, and kappa
or lambda light chains were all conjugated to horseradish peroxidase
and obtained from Southern Biotechnology. All antibodies, conditions,
and reactivities were tested in positive control slides. Apoptag assay358 Cancer Cell 11, 349–360, April 2007 ª2007 Elsevier Inc.(Chemicon) was performed on tissue slides according to the manufac-
turer’s protocols.
Cytospin Preparation, Immunofluorescence, and Transmission
Electron Microscopy
Cytospin slides were prepared using a cytocentrifuge (Thermo Shan-
don), fixed 2 min at RT in acetone:methanol (1:1), and stained using
anti-mouse XBP-1 rabbit polyclonal antibody as a primary antibody
followed by visualization with fluorescein anti-rabbit IgG or directly la-
beled using fluorescein anti-mouse IgG (both from Vector Labs). Im-
munofluorescence was performed on murine kidney samples using
fluorescein (FITC)-conjugated goat antibodies against mouse immu-
noglobulins IgA, IgG, IgM, kappa light chain, and lambda light chain
(Southern Biotechnology). For kidney immunofluorescence, tissue
sections were fixed in glutaraldehyde and processed using fluores-
cein-conjugated goat anti-mouse antibodies for immunoglobulin
heavy chains IgA, IgM, IgG, and light chains kappa or lambda from
Southern Biotechnologies. Transmission electron microscopy of mu-
rine kidney samples was performed using standard procedures after
fixation in Karnovsky’s media.
Flow Cytometry
Red blood cells were removed from single-cell suspensions from
spleens, thymuses, and bone marrow by ammonium chloride treat-
ment (Sigma). Cells were then washed in 3% BSA in PBS and stained
for 30 min on ice with a combination of the following antibodies: B220-
FITC, B220-PE, CD3-PE, CD138-PE, CD8-FITC, CD4-PE, CD21-FITC,
CD43-FITC (BD Biosciences), IgD-FITC, IgM-APC, and CD23-PE
(eBioscience). Cells were washed twice and analyzed on a FACScali-
bur machine (Becton Dickinson) using cell Quest software (Becton
Dickinson). An average of 105 cells was recorded in each case.
In Vitro Proliferation
B220+cells (2 3 105) were plated in triplicate in 96-well plates before
stimulation with LPS (10 mg/ml, Sigma), anti-mouse CD40 (1 mg/ml,
BD Pharmigen), anti-IgM (10 mg/ml, BD Pharmigen), or CD40 and
anti-IgM. After 16 hr of stimulation, the cells were pulsed with [3H]thy-
midine for the final 16 hr of growth before thymidine incorporation was
measured by a scintillation counter. Results are expressed as mean ±
SD of triplicate cultures. Similar results were obtained in three indepen-
dent experiments.
Clonality and Hypermutation Analysis
Southern analysis for clonotypic IgH rearrangements and hypermuta-
tion analysis of the 30 JH4 region of rearranged variable (V) genes were
performed as described previously (Carrasco et al., 2006; McDonald
et al., 2003).
Western Blots
Whole-cell extracts from B220+ splenocytes single- or snap-frozen
tissues were prepared, electroblotted onto PVDF membranes (Amer-
sham), and probed with primary antibodies according to standard pro-
cedures. The anti-mouse XBP-1 rabbit polyclonal antibody (M-186),
anti-b-actin-HRP (C-11), c-FOS (4-10G), and anti-GFP (B-2) antibodies
were from Santa Cruz. Cyclin D1 (DCS6), c-JUN (60A8), and caspase-3
(8G10) antibodies were obtained from Cell Signaling; MCL1 (Rock-
land), PAX5 (Chemicon), and BCL2 (3F11) antibodies from BD Biosci-
ences were also used. Following incubation with horseradish peroxi-
dase-conjugated goat anti-rabbit or anti-mouse secondary antibody
(Pierce), bound immunoglobulins were detected using ECL detection
solutions (Pierce). For consecutive staining with different antisera,
membranes were stripped with Restore western blot stripping buffer
(Pierce). Anti-b-actin immunoreactivity is included as a loading control.
Chemokine, Immunoglobulin, and Paraprotein Determination
Serum chemokine and immunoglobulin concentrations were mea-
sured by ELISA using the Beadlyte mouse multicytokine detection sys-
tem from Upstate. Elevated levels of IL-6 were confirmed using the
Cancer Cell
Mouse Model of Multiple MyelomaQuantikine immunoassay from R&D Systems. All samples were ana-
lyzed in triplicate. Paraproteins (M spikes, extra gradients) were de-
tected using Paragon SPE electrophoresis kit (Beckman Coulter Inc).
Microarray Data
The raw data for expression profiling and the CEL files are available at
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) with
accession number GSE6980.
Supplemental Data
The Supplemental Data include three supplemental figures and one
supplemental table and can be found with this article online at http://
www.cancercell.org/cgi/content/full/11/4/349/DC1/.
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